NexMed Announces Pre-Clinical Results Showing That Its Proprietary Calcipotriene Betamethasone Psoriasis Formulation is Bioeq...
June 15 2010 - 2:48PM
Business Wire
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of
products based on the NexACT® technology, today announced results
from a pre-clinical study showing that calcipotriene 0.005% and
betamethasone dipropionate 0.064%, when formulated with NexACT®,
results in a topical treatment which shows bioequivalency in
efficacy to Talconex®, one of the leading topical treatments
marketed for patients with mild to moderate psoriasis.
NexMed conducted two pre-clinical studies on its NexACT-based
topical psoriasis treatment. The first efficacy study using a
cadaver skin model showed that the NexACT-based formulation of the
two active drugs delivered the same level of drugs (measured in
ug/cm2/hour) as compared to the commercial Talconex® product. In a
second efficacy study, using the DNFB induced allergic contact
dermatitis (ACD) pig model, results showed that the NexACT-based
formulation significantly lowered the clinical inflammation and
erythema score in sick animals. The DNFB induced ACD pig model is
the standard pre-clinical model for testing efficacy of
calcipotriene-based drugs for psoriasis treatments under
development.
Bassam Damaj, Ph.D., President and Chief Executive Officer of
NexMed, stated, “We have a competitive psoriasis treatment under
development. Our NexACT-based formulation is novel and does not
infringe on the marketed topical treatments. Our data, though early
stage, shows bioequivalency to Talconex®, and further supports the
versatility of the NexACT technology and its applicability to a
broad range of disease states. We look forward to commencing
partnering discussions for continued development of this product
candidate.”
About Psoriasis
Psoriasis is a chronic autoimmune disease that appears on the
skin. It occurs when the immune system sends out faulty signals
that speed up the growth cycle of skin cells. There are five types
of psoriasis: plaque, guttate, inverse, pustular and erythrodermic.
The most common form, plaque psoriasis, appears as raised, red
patches or lesions covered with a silvery white buildup of dead
skin cells, called scale. Psoriasis can occur on any part of the
body and is associated with other serious health conditions, such
as diabetes, heart disease and depression. According to the
National Institutes of Health, as many as 7.5 million Americans and
125 million people worldwide, have psoriasis.
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and
is one of the industry's most experienced CROs for in vitro and in
vivo pharmacology services and research models. The Company’s goal
is to generate revenues from the growth of its Discovery
Pre-clinical CRO business, while aggressively seeking to monetize
its proprietary NexACT® drug delivery technology through
out-licensing agreements with pharmaceutical and biotechnology
companies, worldwide. At the same time, NexMed is actively pursuing
partnering opportunities for its NexACT-based treatments for
onychomycosis, psoriasis, sexual dysfunction and cancer. For
further information on NexMed and its subsidiaries, visit the
following websites: http://www.nexmed.com or
http://www.bio-quant.com.
Forward-Looking Statement Safe
Harbor
Statements under the Private Securities Litigation Reform Act:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company
including but not limited to its ability to replicate pre-clinical
results in human clinical trials, whether its product candidates
infringe on third party rights, and whether the it can successfully
partner product candidates.
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Aug 2023 to Aug 2024